Refile: BUZZ-Argenica Therapeutics rises on approval to continue trials from safety board

Argenica Therapeutics

30/01/2025 03:42

(Corrects company name in headline)
    ** Shares of Argenica Therapeutics  AGN.AX  rise 3.1% to
A$0.675, their highest level since Jan. 21
    ** Clinical drug developer announces that the Data Safety
Monitoring Board recommends that trials for its drug ARG-007,
continue without any changes
    ** ARG-007 is a drug to reduce the death of brain tissue
after a stroke
    ** 132,174 shares change hands, 1.4 times the 30-day average
    ** Stock up 7.9% this month, including session's moves

 (Reporting by Manasi Dasa Sundeep in Bengaluru)
 ((Manasi.DasaSundeep@thomsonreuters.com;))